Success Metrics

Active Trials
1(50%)

Phase Distribution

Ph early_phase_1
1
50%
Ph phase_1
1
50%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Early Phase 1First-in-human
1(50.0%)
Phase 1Safety & dosage
1(50.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Terminated(1)

Detailed Status

Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 11 (50.0%)
Phase 11 (50.0%)

Trials by Status

recruiting150%
withdrawn150%

Recent Activity

1 active trials
Showing 2 of 2
withdrawnearly_phase_1

Imaging of Solid Tumors Using DLL3 SPECT

NCT07052760
recruitingphase_1

Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617

NCT07054346

Clinical Trials (2)

Showing 2 of 2 trials
NCT07052760Early Phase 1

Imaging of Solid Tumors Using DLL3 SPECT

Withdrawn
NCT07054346Phase 1

Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617

Recruiting

All 2 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
2